Niagen Bioscience Inc
NASDAQ:NAGEBiotechnology
+$0.11 today
- Market cap
- $153.64M
- Beta
- 2.06
- P/E (TTM)
- 14.9
- EPS (TTM)
- $0.23
Volume 0.52M
Average 0.86M
Returns on capital
Niagen Bioscience Inc management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
22.7%
avg -56.7%
ROIC
15.6%
avg -45.9%
ROA
16.3%
avg -28.7%
Analysis
ROE is currently the strongest return metric at 22.7% versus its period average of -56.7%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Robert N. Fried | Chief Executive Officer & Director | USD 1.21M | 66 | 1.06M | 1.33% |
Ozan Pamir | Chief Financial Officer & Principal Accounting Officer | USD 648.24K | 34 | 11.63K | 0.01% |
Carlos Lopez | Senior Vice President & General Counsel | USD 480.03K | 45 | — | — |
James Lee | Controller | USD 286.49K | 50 | — | — |
Frank Louis Jaksch Jr. | Co-Founder & Chairman | USD 70K | 58 | — | — |
Michiko Kelley | Chief Marketing Officer | — | — | — | — |
Wesley Yu | Vice President of Finance | — | — | — | — |
Andrew Shao | Senior Vice President of Global Regulatory & Scientific Affairs | — | — | — | — |
Kendall Knysch | Head of Media Relations & Partnerships | — | — | — | — |
Chu Yan | Managing Director of Asia Pacific | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 30, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +15.4% (5yr)1 analysts |
| Revenue | N/A | N/A | +21.6% | +12.5% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | +15.0% (5yr)1 analysts |
| EBIT | N/A | N/A | N/A | +25.4% (5yr)1 analysts |
Analysis
Recent growth has been strongest in Revenue at +21.6% over three years. Forward estimates point to EBIT at +25.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Niagen Bioscience Inc compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about NAGE's management, answered from reported figures.
Who manages NAGE?
Niagen Bioscience Inc (NAGE) lists 10 active executives. The top listed executive is Ozan Pamir, Chief Financial Officer & Principal Accounting Officer.
Are NAGE insiders buying or selling?
Recent insider activity shows net buying of $5.81M.
Continue the stock analysis
Jump to another research area for this company.